Angioedema associated with dipeptidyl peptidase-IV inhibitors.
Nicoletta CassanoEustachio NettisElisabetta Di LeoFrancesca AmbrogioGino A VenaCaterina FotiPublished in: Clinical and molecular allergy : CMA (2021)
This risk of angioedema associated with the use of gliptins has mostly been related to the concurrent administration of ACEIs, and has been considered rare, but it might be underestimated and underreported. The role of additional risk factors or drug interactions deserves further investigations. Caution should be taken when considering the use of DPP-IV inhibitors in patients treated with ACEIs or presenting with other known risk factors for angioedema.